Treatment outcome in older patients with childhood acute myeloid leukemia

Cancer

Volumn 118, Issue 24, 2012, Pages 6253-6259

  Rubnitz, Jeffrey E ^a,b   Pounds, Stanley ^a   Cao, Xueyuan ^a   Jenkins, Laura ^a   Dahl, Gary ^c   Bowman, W Paul ^d   Taub, Jeffrey W ^e   Pui, Ching Hon ^a,b   Ribeiro, Raul C ^a,b   Campana, Dario ^f   Inaba, Hiroto ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^d Stanford Cancer Center ^*  (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

acute myeloid leukemia; adolescents; age; pediatrics; prognosis

Indexed keywords

CLADRIBINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLADRIBINE; COMBINED MODALITY THERAPY; CYTARABINE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84870709830     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27659     Document Type: Article

References (19)

1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010; 28: 2625-2634.
2. Bleyer A,. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007; 57: 242-255.
3. Wood WA, Lee SJ,. Malignant hematologic diseases in adolescents and young adults. Blood. 2011; 117: 5803-5815.
4. Sender LS,. A new journal to improve care for adolescent and young adult oncology patients and survivors. J Adolesc Young Adult Oncol. 2011; 1: 1-2.
5. Razzouk BI, Estey E, Pounds S, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006; 106: 2495-2502.
6. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11: 543-552.
7. Rubnitz JE, Crews KR, Pounds S, et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia. 2009; 23: 1410-1416.
8. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001; 19: 2804-2811.
9. Kaplan EL, Meier P,. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
10. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35: 1-39.
11. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
12. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008; 113: 376-382.
13. Creutzig U, Buchner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008; 112: 562-571.
14. Horibe K, Tsukimoto I, Ohno R,. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001; 15: 1256-1261.
15. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J,. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007; 110: 3532-3539.
16. Sung L, Gamis A, Alonzo TA, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009; 115: 1100-1108.
17. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T,. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004; 22: 4384-4393.
18. Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004; 101: 1677-1684.
19. Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U,. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007; 109: 936-943.